Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Als crawled time : 12:00 save search
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
Published: 2023-12-21 (Crawled : 12:00) - globenewswire.com
CLNN | $0.325 -1.93% 300K
|
|
| O: -34.37%
H: 3.49%
C: -6.8%
au8 label als biomarker treatment extension trial platform
Clene Provides Update on ALS Clinical Development Meeting With FDA
Published: 2023-12-21 (Crawled : 12:00) - globenewswire.com
CLNN | $0.325 -1.93% 300K
|
|
| O: -34.37%
H: 3.49%
C: -6.8%
fda als update meeting
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia
Published: 2023-11-17 (Crawled : 12:00) - prnewswire.com
BCLI | $0.5325 -2.95% 500K
|
Health Technology
|
| O: -1.25%
H: 7.31%
C: 3.57%
als cell research therapeutics
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
Published: 2023-08-01 (Crawled : 12:00) - globenewswire.com
KTTA | $7.15 170
|
|
| O: 0.46%
H: 0.0%
C: -1.61%
als sciences therapeutics results study
Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
Published: 2023-06-26 (Crawled : 12:00) - globenewswire.com
CLNN | $0.325 -1.93% 300K
|
|
| O: 1.9%
H: 3.04%
C: -1.86%
au8 als publication treatment phase 2
Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting
Published: 2023-04-11 (Crawled : 12:00) - globenewswire.com
CLNN | $0.325 -1.93% 300K
|
|
| O: 0.92%
H: 0.0%
C: -1.82%
au8 als meeting
New Data Show CNM-Au8® Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial
Published: 2023-03-06 (Crawled : 12:00) - globenewswire.com
CLNN | $0.325 -1.93% 300K
|
|
| O: 6.67%
H: 1.56%
C: 0.0%
au8 rescue-als disease extension als trial show
CureVac begrüßt Dr. Myriam Mendila als neuen Chief Development Officer
Published: 2023-02-01 (Crawled : 12:00) - curevac.com
GLAXF | $20.2 510
|
Health Technology
|
| O: 1.91%
H: 0.0%
C: -1.42%
GSK | $40.035 -1.15% 1.5M
|
Health Technology
|
| O: 0.0%
H: 1.5%
C: 0.65%
CVAC | $2.72 2.64% 290K
|
Health Technology
|
| O: 0.74%
H: 8.96%
C: 8.96%
als
Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
Published: 2022-07-26 (Crawled : 12:00) - prnewswire.com
IONS | $41.69 0.34% 160K
|
Health Technology
|
| O: 1.96%
H: 0.2%
C: -2.61%
fda drug genetic als application grants review
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
Published: 2022-07-26 (Crawled : 12:00) - globenewswire.com
IONS | $41.69 0.34% 160K
|
Health Technology
|
| O: 1.96%
H: 0.2%
C: -2.61%
BIIB | $196.6 -0.1% 350K
|
Health Technology
|
| O: -0.42%
H: 3.54%
C: 2.01%
fda drug genetic als application grants review
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
Published: 2022-06-13 (Crawled : 12:00) - biospace.com/
AMLX | $1.995 -3.62% 1.1M
|
|
| O: -3.25%
H: 15.66%
C: -0.69%
treatment canada health als approval
Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium
Published: 2022-06-08 (Crawled : 12:00) - biospace.com/
MITO | $0.32 0.25%
|
Health Technology
|
| O: 58.35%
H: 11.2%
C: -14.06%
sbt-272 disease als symposium
Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs
Published: 2022-05-19 (Crawled : 12:00) - biospace.com/
VYGR | $8.11 -1.58% 130K
|
Health Technology
|
| O: -1.86%
H: 3.8%
C: 0.95%
preclinical als therapy results pre-clinical
Provention Bio Announces FDA Acceptance of the Biologics License Application (BLA) Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-Risk Individuals
Published: 2022-03-21 (Crawled : 12:00) - biospace.com/
PRVB | $24.98 0.08% 9.1M
|
Health Technology
|
| O: 2.45%
H: 0.75%
C: -7.29%
fda als risk application license diabetes fda acceptance submission teplizumab resubmission
Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer
Published: 2022-03-21 (Crawled : 12:00) - crinetics.com
CRNX | $43.66 -0.05% 210K
|
Health Technology
|
| O: 1.76%
H: 0.0%
C: -3.5%
als
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-03-21 (Crawled : 12:00) - biospace.com/
MRNS | $1.28 -1.54% 11M
|
Health Technology
|
| O: -10.0%
H: 8.22%
C: -2.89%
als financial results report results
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
Published: 2022-03-21 (Crawled : 12:00) - biospace.com/
FUSN | $21.25 -0.14% 370K
|
Health Technology
|
| O: 4.57%
H: 0.83%
C: -2.42%
DFFN 4 | $6.6 11.68% -34.32% 350K
|
Health Technology
|
| O: 0.37%
H: 0.0%
C: -5.07%
als financial results report results
Global 5.1% CAGR of Metal Finishing Chemicals Market Size to Surpass USD 19.12 Bn By 2028: Industry Share, Trends, Forecast Report by ZMR
Published: 2022-03-21 (Crawled : 12:00) - prnewswire.com
CTS | $44.72 -1.65% 42K
|
Electronic Technology
|
| O: 0.14%
H: 0.47%
C: -1.49%
als report
VERSABANK'S 2022 ANNUAL MEETING TO BE HELD AT TMX MARKET CENTRE, 120 ADELAIDE STREET WEST, TORONTO - MEETING WILL ALSO BE LIVE STREAMED
Published: 2022-03-18 (Crawled : 12:00) - prnewswire.com
VBNK | $10.06 -1.85% -1.89% 49K
|
Finance and Insurance
|
| O: -1.93%
H: 6.53%
C: 6.53%
als
ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting
Published: 2022-03-18 (Crawled : 12:00) - biospace.com/
ASLN | $0.487 -3.62% 92K
|
Health Technology
|
| O: 6.42%
H: 0.99%
C: -2.02%
america als atopic dermatitis dermatitis derm presentation roof
Gainers vs Losers
| 53% | 47% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.